NAT10 and E2F1 Orchestrate CKAP5-Mediated Progression in Esophageal Squamous Cell Carcinoma.
Key Points
The research aims to identify and understand the roles of NAT10 and E2F1 in ESCC progression through the CKAP5 pathway.
Mechanistic analysis of NAT10/CKAP5 and E2F1/CKAP5 interactions.
Experimental validation of pathway involvement in cell models of ESCC.
Assessment of potential therapeutic targets through inhibition of identified pathways.
NAT10 and E2F1 were found to significantly promote CKAP5-mediated progression of ESCC.
Targeting these pathways may offer new therapeutic strategies against esophageal squamous cell carcinoma.
Abstract
Our study mechanistically elucidates the NAT10/CKAP5 and E2F1/CKAP5 axes as critical novel pathways driving ESCC progression, providing promising therapeutic targets for this malignancy.